A new fenofibrate formulation: Results of six single-dose, clinical studies of bioavailability under fed and fasting conditions

Clinical Therapeutics

Volumn 26, Issue 9, 2004, Pages 1456-1469

  Guivarc'h, Pol Henri ^a,b,c   Vachon, Michael G ^a,c   Fordyce, Diana ^b  

^a SkyePharma Inc   (United States)

^b 10 East 63rd Street   (United States)

^c CATO RESEARCH LTD   (United States)

Author keywords

absorption; adverse events; bioavailability; fat effect; fenofibric acid; food effect; Insoluble Drug Delivery Microparticle fenofibrate; microcoated fenofibrate; micronized fenofibrate; pharmacokinetics; safety; tolerability

Indexed keywords

FENOFIBRATE; LIPIDIL MICRO; LIPIDIL SUPRA; LOFIBRA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DYSPEPSIA; ELBOW DISEASE; ELBOW PAIN; ESOPHAGITIS; FEEDING; FEMALE; FLATULENCE; FOOD; HEADACHE; HUMAN; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PHARYNGITIS; PRURITUS; RASH; REGRESSION ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; THORAX PAIN; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTILIPEMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DIETARY FATS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PROCETOFEN; RANDOMIZED CONTROLLED TRIALS; TABLETS;

EID: 9744245294     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.09.015     Document Type: Article

References (29)

1. Keating G.M., and Ormrod D. Micronised fenofibrate: An updated review of its clinical efficacy in the management of dyslipidaemia Drugs 62 2002 1909 1944
2. Adkins J.C., and Faulds D. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia Drugs 54 1997 615 633
3. Guay D.R. Update on fenofibrate Cardiovasc Drug Rev 20 2002 281 302
4. Najib J. Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation Clin Ther 24 2002 2022 2050
5. Ramjattan B.R., Callaghan D.J., and Theiss U. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: A pooled analysis of two open-label trials Clin Ther. 24 2002 1105 1116
6. Steiner G., and Diabetes Atherosclerosis Intervention Study Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
7. Desager J.P., and Harvengt C. Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers Int J Clin Pharmacol Biopharm 16 1978 570 574
8. (Suppl) Munoz A., Guichard J.P., and Reginault P. Micronised fenofibrate Atherosclerosis 110 1994 S45 S48
9. Chicago, Ill. Achari R., Chira T., and Pan W. Bioavailability of fenofibric acid from fenofibrate capsules Paper presented at: 29th Annual Meeting of the American College of Clinical Pharmacology September 17-19, 2000
10. TriCor capsules 2000 Abbott Laboratories, Inc Abbott Park, Ill
11. TriCor tablets 2001 Abbott Laboratories, Inc Abbott Park, Ill
12. Lipidil 1994 Fournier Pharma, Inc Montreal, QC
13. Lipidil Micro 1994 Fournier Pharma, Inc Montreal, QC
14. Lipidil Supra 2000 Fournier Pharma, Inc Montreal, QC
15. Lipanthyl 1998 Fournier Pharma, Inc Paris, France
16. LoFibra 2003 Gate Pharma, Inc North Wales, Pa
17. McEvoy G.K. AHFS Drug Information 2000 2000 American Society of Health System Pharmacists Bethesda, Md
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
19. (Suppl) Desager J.P., Horsmans Y., Vandenplas C., and Harvengt C. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters mea sured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days Atherosclerosis 124 1996 S65 S73
20. Raslov K., Dubovsk D., Mongiellov V., and Trnovec T. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cho lesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia Eur J Clin Pharmacol 52 1997 101 106
21. Mishra A.K., Vachon M.G., and Guivarc'h P.H. IDD technology: Oral delivery of water-insoluble drugs using phospholipid-stabilized microparticulate IDD formu lations[eb Rathbone M.J. Hadgraft J. Roberts M.S. Modified-Release Drug Delivery Technology 2002 Marcel Dekker New York 151 175
22. Available at US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products--general considerations Accessed June 22, 2004
23. Available at US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry. Statistical approaches to establishing bioequivalence Accessed June 22, 2004
24. Available at US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry. Food-effect bioavail ability and fed bioequivalence studies Accessed June 22, 2004
25. Available at Halls S.B. About the "Metropolitan Life" tables of height and weight Accessed July 6, 2004 weight/met.htm
26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice Guidelines: Consolidated Guideline Catalogue no. H42-2/67-11-1997E. 1997 Health Canada, Therapeutic Products Programme Ottawa, ON
27. Available at World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Accessed July 7, 2004
28. Masnatta L.D., Cuniberti L.A., Rey R.H., and Werba J.P. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography J Chromatogr B Biomed Appl 687 1996 437 442
29. Available at US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry Bioanalytical method validation Accessed June 22, 2004